TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18327427

Group type: EXPERIMENTAL
Intervention: Clarithromycin 15 mg/kg/day, twice a day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Erythromycin 30-50 mg/kg/day, four times daily
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Clarithromycin and Erythromycin
Number of subjects: 97
Study: 16360994

Group type: EXPERIMENTAL
Intervention: IV NAC 300 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: IV NAC 600 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: IV fluid alone (Control)
Number of subjects: 65
Study: 12560887

Group type: EXPERIMENTAL
Intervention: Walking group (11 subjects)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Resting group (6 subjects)
Number of subjects: 17
Study: 10338049

Group type: EXPERIMENTAL
Intervention: 250 mg/kg intravenous immunoglobulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mg/kg intravenous immunoglobulin
Number of subjects: 0
Study: 8620338

Group type: EXPERIMENTAL
Intervention: Colestipol (20 g/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Colestipol (20 g/d) + Simvastatin (20 mg/d)
Number of subjects: 8
Study: 2015715

Group type: EXPERIMENTAL
Intervention: Intraoperative and postoperative intravenous urokinase
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Long-term sodium warfarin therapy
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 344
Study: 7006581

Group type: EXPERIMENTAL
Intervention: Timolol alone, supplemented after two weeks with epinephrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epinephrine treatment alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Simultaneous timolol treatment with epinephrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Timolol and epinephrine combined therapy
Number of subjects: 16
Study: 30614289

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg) plus Myoinositol (600 mg) three times a day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metformin (500 mg) three times a day
Number of subjects: 120
Study: 28550080

Group type: EXPERIMENTAL
Intervention: Intensive phosphate goal of 2.33‐4.66 mg/dl (0.75‐1.50 mmol/L)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Liberalized target of 6.20‐7.75 mg/dl (2.00‐2.50 mmol/L)
Number of subjects: 104
Study: 25525835

Group type: EXPERIMENTAL
Intervention: Prebiotic mixture (9 g of galactooligosaccharides [GOS] + 1 g of maltodextrins; daily for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control medium (in vitro)
Number of subjects: 0
Study: 23831050

Group type: EXPERIMENTAL
Intervention: ARP1 (15-30 mg/kg/day)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 176
Study: 21331949

Group type: EXPERIMENTAL
Intervention: Combination of tryptophan (Trp) and arginine (Arg) in diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19127071

Group type: EXPERIMENTAL
Intervention: Exposure to 4,000 grains/m3 of JC pollen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exposure to 8,000 grains/m3 of JC pollen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exposure to 12,000 grains/m3 of JC pollen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Exposure to 0 grains/m3 of JC pollen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of symptoms between summer and winter studies
Number of subjects: 24
Study: 17942035

Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg/8 h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/24 h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg/8 h) plus Melatonin (3 mg/24 h)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (lactose 50 mg/8 h)
Number of subjects: 120
Study: 15864246

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 4395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4395
Study: 12081590

Group type: EXPERIMENTAL
Intervention: Ash-Split catheter (MedComp)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Opti-Flow catheter (Bard Access Systems)
Number of subjects: 132
Study: 9651260

Group type: EXPERIMENTAL
Intervention: Intravenous heroin (median 480 mg daily) and health/psychosocial services
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional drug treatment (usually methadone maintenance)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous heroin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 51
Study: 8580671

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2693013

Group type: EXPERIMENTAL
Intervention: 1 h/wk training program (exercise group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonphysical activities (nonexercise group)
Number of subjects: 32
Study: 910806

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no transfusions)
Number of subjects: 30
Study: 31611547

Group type: EXPERIMENTAL
Intervention: Customized 3D-printed single-sided lateral wedge insole (CLWI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional single insert
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unilateral flat insoles (Control)
Number of subjects: 30
Study: 27517267

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 383

Group type: COMPARATOR
Intervention: Taxane
Number of subjects: 383
Study: 26494444

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 4.5 mg/kg
Number of subjects: 13
Study: 23100117

Group type: EXPERIMENTAL
Intervention: E10.5% probiotic
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: E21.5% probiotic
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: E32.0% probiotic
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 2.0% probiotic
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All experimental groups (E10.5%, E21.5%, E32.0%)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 21148765

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 10
Study: 18974711

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 11 weeks, consisting of 30 inspiratory efforts performed twice a day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (basic training only)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 15
Study: 16669849

Group type: EXPERIMENTAL
Intervention: Paroxetine (10-40 mg day-1)
Number of subjects: 171
Study: 12792293

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 30
Study: 11111206

Group type: EXPERIMENTAL
Intervention: α1-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive α1-blockers (terazosin and doxazosin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alfuzosin and tamsulosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study: 8975873

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1280145

Group type: EXPERIMENTAL
Intervention: Inerpan
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional dressings (petroleum jelly gauze, petroleum jelly gauze with antibiotics, silver sulphadiazine cream)
Number of subjects: 62
Study: 3871597

Group type: EXPERIMENTAL
Intervention: Continuous prophylaxis with trimethoprim‐sulfamethoxazole
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intermittent self‐administered therapy (single‐dose trimethoprim‐sulfamethoxazole)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patient-administered therapy with single-dose trimethoprim‐sulfamethoxazole
Number of subjects: 38
Study: 29128419

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27630009

Group type: EXPERIMENTAL
Intervention: READY-Girls preconception counseling (RGPC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 136
Study: 24576793

Group type: EXPERIMENTAL
Intervention: Drospirenone-containing combined oral contraceptives (DRSP24d)
Number of subjects: 85109

Group type: EXPERIMENTAL
Intervention: Drospirenone-containing combined oral contraceptives (DRSP21d)
Number of subjects: 85109

Group type: EXPERIMENTAL
Intervention: Non-drospirenone oral contraceptives (non-DRSP)
Number of subjects: 85109

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing oral contraceptives (LNG)
Number of subjects: 85109
Study: 22491665

Group type: EXPERIMENTAL
Intervention: Thoracotomy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Surgical procedures (overall)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Non-screening series (comparison)
Number of subjects: 198
Study: 20146168

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy (GHRT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study: 18780883

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 0
Study: 15747701

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sedation with alfentanil and midazolam plus paracervical block
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sedation with remifentanil plus paracervical block
Number of subjects: 90
Study: 15333399

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (BH) - four puffs applied to the pharynx 30 min before operation and 5 min before induction of anesthesia.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Distilled water (control) - applied with the same protocol as BH.
Number of subjects: 100
Study: 11144372

Group type: EXPERIMENTAL
Intervention: DTaP/HepB vaccine used to reconstitute lyophilized PRP‐T vaccine administered as a single injection
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: DTaP/HepB vaccine and PRP‐T vaccine administered as two separate injections
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: DTaP, HepB and PRP‐T vaccines administered as three separate injections
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Booster dose of Hib conjugate vaccine given at 11 to 15 months of age
Number of subjects: 405
Study: 9122732

Group type: EXPERIMENTAL
Intervention: recombinant interleukin-2 (rIL-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: recombinant interleukin-2 (rIL-2) with coadministration of lymphokine-activated killer (LAK) cells
Number of subjects: 0
Study: 8330602

Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 micrograms kg‐1 (n = 33)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Morphine 50 micrograms kg‐1 (n = 32)
Number of subjects: 65
Study: 3781681

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% plain
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with epinephrine 1:100,000
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Norepinephrine 1:20,000
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 75
Study: 30834513

Group type: EXPERIMENTAL
Intervention: ATB‐346 (250 mg once daily)
Number of subjects: 244

Group type: COMPARATOR
Intervention: naproxen (550 mg twice daily)
Number of subjects: 244
Study: 29523571

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for 4-6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 40
Study: 27502865

Group type: EXPERIMENTAL
Intervention: Intravenous glucose-insulin-potassium (GIK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 0
Study: 25335328

Group type: EXPERIMENTAL
Intervention: Jiangzhi Tongluo Soft Capsule (JTSC) combined with Atorvastatin Calcium Tablet (ACT)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Atorvastatin Calcium Tablet (ACT) alone
Number of subjects: 138
Study: 22215753

Group type: EXPERIMENTAL
Intervention: Increased lactate dehydrogenase (≥ 2 × upper limit of normal [ULN])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary site involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow/CNS positive disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age (≥ 15 years)
Number of subjects: 0
Study: 19717477

Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanate (n = 212)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Moxifloxacin (n = 215)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Moxifloxacin for predominantly 5 days (n = 127)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Moxifloxacin for predominantly 10 days (n = 87)
Number of subjects: 427
Study: 18511873

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1095
Study: 16007327

Group type: EXPERIMENTAL
Intervention: Monthly ibandronate 50 mg/50 mg
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Monthly ibandronate 100 mg
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Monthly ibandronate 150 mg
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Daily ibandronate 2.5 mg
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: All monthly regimens
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: 100 mg and 150 mg monthly regimens
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 1609
Study: 12910557

Group type: EXPERIMENTAL
Intervention: NSAIDs (specifically indomethacin, meclofenamate, piroxicam)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High dosages of NSAIDs
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Other NSAIDs (regardless of dosage)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11776606

Group type: EXPERIMENTAL
Intervention: Nasea
Number of subjects: 98

Group type: COMPARATOR
Intervention: Kytril
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nasea and Kytril
Number of subjects: 98
Study: 8874334

Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg/d for 2 years plus 6 months of intravenous chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Tamoxifen 30 mg/d for 2 years
Number of subjects: 705
Study: 1353510

Group type: EXPERIMENTAL
Intervention: Chlorhexidine detergent shower
Number of subjects: 3482

Group type: COMPARATOR
Intervention: Placebo detergent shower
Number of subjects: 3482
Study: 6538013

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol administration
Number of subjects: 15

Group type: COMPARATOR
Intervention: Propranolol therapy
Number of subjects: 15
Study: 30517889

Group type: EXPERIMENTAL
Intervention: Active CPAP treatment for 12 weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sham-CPAP (sub‐therapeutic) device for 12 weeks
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Active CPAP treatment
Number of subjects: 210
Study: 29506208

Group type: EXPERIMENTAL
Intervention: Chair-based pedal exercises (5 min three times a day with minimal supervision)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study: 26358717

Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 44
Study: 25142121

Group type: EXPERIMENTAL
Intervention: HeartNetCare‐HF™ (HNC)
Number of subjects: 715
Study: 22381532

Group type: COMPARATOR
Intervention: Standard colonoscope
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Magnetic endoscopic imaging (MEI) colonoscope
Number of subjects: 160
Study: 20616687

Group type: EXPERIMENTAL
Intervention: Microplasmin 75 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 125 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 175 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microplasmin 125 microg (repeated up to 3 times)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 60
Study: 17532829

Group type: EXPERIMENTAL
Intervention: Nasal budesonide
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Oral montelukast
Number of subjects: 4

Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Nasal sodium cromoglycate
Number of subjects: 4
Study: 15580472

Group type: COMPARATOR
Intervention: Physiotherapeutic pelvic floor training (CT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of CT with transanal electrical stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of CT with perineal electrical stimulation
Number of subjects: 60
Study: 11994056

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous midazolam (5 mg)
Number of subjects: 6
Study: 10440916

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 875
Study: 7561442

Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaria
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (no herbal therapy)
Number of subjects: 123
Study: 2161633

Group type: COMPARATOR
Intervention: Thoracic radiotherapy alone (60 Gy over 6 weeks)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Thoracic radiotherapy plus vindesine (3 mg/m2 weekly for 6 weeks)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Vindesine alone (3 mg/m2 weekly for 6 weeks)
Number of subjects: 319
Study: 498825

Group type: EXPERIMENTAL
Intervention: Terbutaline 2.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ephedrine 25 mg
Number of subjects: 0
Study: 31267360

Group type: COMPARATOR
Intervention: Circulating NK cells in diffuse/mixed-type AGC (n=27)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Circulating Tregs in diffuse/mixed-type AGC (n=27)
Number of subjects: 67

Group type: COMPARATOR
Intervention: CD8+ TILs in diffuse/mixed-type AGC (n=27)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High circulating NK cell counts (>17%)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High CD8+ TIL counts (>31 cells/field)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CD8+ TILs after adjustment for confounding factors
Number of subjects: 67
Study: 30991718

Group type: EXPERIMENTAL
Intervention: Chokeberry juice with high-dose polyphenols (1177.11 mg GAE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chokeberry juice with low-dose polyphenols (294.28 mg GAE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo drink (polyphenol-free)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chokeberry juice (both doses)
Number of subjects: 100
Study: 28532539

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with platinum chemotherapy
Number of subjects: 81
Study: 25592197

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 23727257

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 IV Q3 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Docetaxel + Vandetanib (100 mg PO daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 29
Study: 21368320

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (non-AT group)
Number of subjects: 55
Study: 19389877

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapoxetine 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapoxetine 240 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17498486

Group type: EXPERIMENTAL
Intervention: High-dose Astragalus injection with cyclophosphamide (CTX)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) alone
Number of subjects: 43
Study: 15483371

Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g alcohol/kg body weight)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 18044996

Group type: EXPERIMENTAL
Intervention: Step-wise shockwave lithotripsy (SWL) with gradually increased output voltage (11, 12, and 13 kV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional shockwave lithotripsy (SWL) at 13 kV
Number of subjects: 50
Study: 10926792

Group type: EXPERIMENTAL
Intervention: Thrombocytosis (platelet count >400 x 10(9)/liter)
Number of subjects: 291

Group type: COMPARATOR
Intervention: No thrombocytosis
Number of subjects: 291
Study: 8767986

Group type: EXPERIMENTAL
Intervention: Thoracic vent
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional intercostal tube drainage
Number of subjects: 30
Study: 1929035

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vancomycin plus rifampin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study: 7059752

Group type: EXPERIMENTAL
Intervention: Stress (random shock)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-stress conditions
Number of subjects: 0
Study: 31298571

Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm) enucleation of the prostate (DiLEP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 126
Study: 29807060

Group type: EXPERIMENTAL
Intervention: Zirconia-ceramic FDPs (ZC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Metal-ceramic FDPs (MC)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both ZC and MC FDPs
Number of subjects: 58